RxSight Surpasses Revenue Forecasts and Appoints New Financial Leadership

The medical technology firm RxSight has concluded its 2025 fiscal year on a high note, delivering preliminary revenue that exceeded its own projections. The company is now positioning itself for its next growth chapter with a key leadership appointment aimed at leveraging deep industry expertise.

RxSight's preliminary financial results for the full year 2025 reveal significant outperformance. The company generated approximately $134.5 million in revenue, surpassing its previously guided range of $125 million to $130 million. The fourth quarter contributed an estimated $32.6 million to this total, indicating a strong finish to the year.

This growth was primarily fueled by the commercial adoption of its Light Adjustable Lens (LAL) systems. For the full year, the company sold 109,615 LAL units, representing a 12% increase over 2024 volumes. In the fourth quarter alone, sales reached 28,611 LAL units. Furthermore, 25 of the companion Light Delivery Devices (LDD) were sold during the same period, underscoring the expanding clinical utilization of its proprietary technology.

Strategic Management Transition Underway

Concurrent with its operational success, RxSight has initiated a strategic transition in its executive suite. On January 11, 2026, Mark Wilterding assumed the role of Chief Financial Officer. He succeeds Shelley Thunen, who is departing after nearly a decade with the company.

Should investors sell immediately? Or is it worth buying Rxsight?

Wilterding brings more than 25 years of financial leadership experience from prominent medical device corporations, including Medtronic and Edwards Lifesciences. His appointment is viewed as a move to strengthen the financial strategy as RxSight seeks to capitalize on its current momentum and accelerate its expansion plans.

Looking Ahead: Final Results and Market Position

Following its presentation at the J.P. Morgan Healthcare Conference in January, the investment community is now awaiting the release of RxSight's final, audited financial statements for fiscal year 2025. The complete annual report is scheduled for publication later in February.

These final figures will provide a clearer picture of the company's financial health as it moves forward under new financial leadership, aiming to solidify and extend its market position in ophthalmic technology.